Archive for February, 2013

Spinal Fluid Proteins

February 23, 2013

Researchers at six institutions led by the University of Medicine and Dentistry of New Jersey and Pacific Northwest National Laboratory reported finding 738 unique protein markers in spinal fluid samples collected from 43 CFS patients and compared to samples from 25 neurologic post-treatment Lyme disease patients […]

FDA Drug Development Workshop Dates Announced

February 21, 2013

This notice was posted to the FDA’s website and circulated to the Department of Health and Human Services CFS Advisory Committee’s public listserv. Inquiries should be directed to FDA at FDA Workshop on Drug Development for Chronic Fatigue Syndrome (CFS) and Myalgic Encephalomyelitis (ME) […]


February 19, 2013

Researchers in Kansas and Germany report results of a large population survey of 2,445 people selected randomly from the German population. 2.1% of the population met 2010 criteria for FM. Prevalence was similar in women and men, a difference from past studies that showed more […]

Serious Unmet Need Demands Collaborative Action

February 7, 2013

Originally posted on February 7, 2013; updated on March 4, 2013 and again on March 13, 2013 The recent decision by the Food and Drug Administration (FDA) to decline the latest New Drug Application (NDA) from Hemispherx Biopharma for Ampligen is a great disappointment to […]

The Waiting Game: Ampligen Decision Unknown

February 2, 2013

Today, Feb. 2, 2013, is the expected date for the U.S. Food and Drug Administration (FDA) to deliver its decision on the application by Hemipsherx Biopharma to market rintatolimod (Ampligen) for the treatment of chronic fatigue syndrome (CFS). The deadline for a decision is driven […]

Manual Therapy in CFS: Part 2 of 2

February 1, 2013

By Peter C. Rowe, MD, Kevin R. Fontaine, PhD and Rick L. Violand, PT In Part 1 of this two-part series, we outlined the series of observations of patients with chronic fatigue syndrome (CFS) that has helped us develop a new approach based on advances […]